Skip to main content
NEO
NASDAQ Industrial Applications And Services

NeoGenomics Swings to Q2 Profit, Raises Full-Year Outlook on 11% Revenue Growth

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$14.182
Mkt Cap
$1.745B
52W Low
$4.72
52W High
$15.57
52W Position info
200% above low
Off High info
8.9% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

NEO has more than doubled off its 52-week low of $4.72.

Summary

NeoGenomics posted Q2 revenue of $201.7M (+11% YoY), swung to a GAAP profit, and raised full-year guidance. The quarter also closed out the DOJ settlement and a convertible notes refinancing that strengthens the balance sheet.


Key Events · Earnings and Guidance · NEO

  • Q2 Revenue +11%, Swings to Profit

    Revenue of $201.7M grew 11.2% YoY, gross margin expanded to 45.6%, and GAAP net income reached $2.2M vs. a $45.1M loss in Q2 2025. Operating expenses fell 18.6%.

  • Full-Year Guidance Raised

    Management increased its 2026 revenue and adjusted EBITDA outlook, reflecting sustained commercial momentum and cost discipline.

  • Convertible Notes Refinancing Completed

    Issued $316.25M of 0.75% notes due 2032, used proceeds to repurchase $262.9M of 2028 notes, recognizing an $11.2M gain. Concurrently repurchased 2.38M shares for $25M.

  • DOJ Settlement Finalized at $10M

    The civil settlement was finalized at $10.0M, down from the $11.2M reserve, resulting in a $1.2M benefit to Q2 earnings. Payment is due in Q3 2026.


Analysis · NEO · Industrial Applications And Services

NeoGenomics delivered a clean beat-and-raise quarter. Revenue grew 11% to $201.7 million, gross margins expanded three points to 45.6%, and the company posted GAAP net income of $2.2 million versus a $45 million loss a year ago. Operating expenses fell sharply as legal and professional fees declined and a $1.2 million benefit from the DOJ settlement reserve reversal dropped to the bottom line. Management raised full-year revenue and adjusted EBITDA guidance — a concrete signal that the commercial momentum and cost discipline are sustainable. The balance sheet was also transformed: a $316 million convertible notes offering refinanced most of the 2028 notes at a gain, and the company bought back $25 million of stock. With cash from operations turning positive and the DOJ overhang resolved, the investment thesis shifts from turnaround to execution on profitable growth.

At the time of this filing, NEO was trading at $14.18 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $4.72 to $15.57. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NEO - Latest Insights

NEO
Jul 28, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.25
Real-time Price: $13.87 info
Change: -$0.380 (-3%) info
Market Cap: $1.745B info
NEO
Jul 20, 2026, 5:27 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.24
Real-time Price: $13.87 info
Change: -$0.370 (-3%) info
Market Cap: $1.745B info
NEO
Jul 20, 2026, 5:23 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $14.24
Real-time Price: $13.87 info
Change: -$0.370 (-3%) info
Market Cap: $1.745B info
NEO
Jun 25, 2026, 7:10 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.92
Real-time Price: $13.87 info
Change: +$0.950 (+7%) info
Market Cap: $1.745B info
NEO
Jun 22, 2026, 5:17 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.20
Real-time Price: $13.87 info
Change: +$2.67 (+24%) info
Market Cap: $1.745B info